Evaluation of Leukocytosis, Anemia, and Thrombocytosis
This triad of findings requires immediate peripheral blood smear review and consideration of acute leukemia versus myeloproliferative neoplasm, with bone marrow biopsy being the definitive next step if blasts are present or if a primary hematologic disorder is suspected.
Initial Diagnostic Approach
The combination of elevated white count, low hemoglobin, and elevated platelets is concerning for a primary hematologic malignancy rather than reactive processes. Your immediate workup should proceed algorithmically:
Step 1: Peripheral Blood Smear Review (Mandatory)
- Look specifically for: blast cells, immature granulocytes, nucleated red blood cells, and megakaryocyte morphology 1
- The presence of any blasts mandates urgent hematology consultation and bone marrow evaluation 2
- Assess whether the leukocytosis shows a monomorphic (concerning for malignancy) versus polymorphic (reactive) pattern 2
Step 2: Complete Blood Count with Differential
Obtain the following critical parameters:
- Absolute neutrophil count, lymphocyte count, and blast percentage 1
- Platelet count >450 × 10⁹/L confirms thrombocytosis 3
- White blood cell count >50 × 10⁹/L with thrombocytosis >2000 × 10⁹/L strongly suggests chronic myeloid leukemia 4
Step 3: Essential Laboratory Tests
Perform immediately:
- Lactate dehydrogenase (tumor lysis syndrome marker) 1
- Comprehensive metabolic panel including phosphate and uric acid 1
- Coagulation panel (PT, PTT, fibrinogen) to detect disseminated intravascular coagulation if acute promyelocytic leukemia suspected 1
- C-reactive protein and ferritin levels to assess for reactive causes 3
Step 4: Risk Stratification Based on Findings
If blasts are present on smear:
- Proceed directly to bone marrow aspiration and core biopsy 1
- Obtain fresh bone marrow for flow cytometry, cytogenetics (karyotype), FISH, and molecular testing 1
- The flow cytometry panel must distinguish AML, ALL, and acute leukemia of ambiguous lineage 1
If no blasts but persistent cytopenias with thrombocytosis:
- Test for JAK2 V617F mutation first, then CALR and MPL mutations if negative 3, 5
- Consider BCR-ABL1 testing (Philadelphia chromosome) for chronic myeloid leukemia, especially if basophilia or eosinophilia present 4, 5
- Bone marrow biopsy remains necessary to exclude myeloproliferative neoplasms or prefibrotic myelofibrosis 3, 5
Critical Pitfalls to Avoid
Do not attribute this triad to reactive causes without excluding malignancy. While post-splenectomy or infection can cause leukocytosis and thrombocytosis, the addition of anemia makes a primary hematologic disorder more likely 4. The platelet-to-WBC ratio <20 suggests infection, but ratios outside this range or extreme elevations (WBC >50 × 10⁹/L) point toward chronic myeloid leukemia 4.
Do not delay bone marrow biopsy if the peripheral smear is concerning. Even if you cannot obtain adequate bone marrow aspirate, touch imprint preparations from core biopsy can be used for flow cytometry and genetic studies 1.
Specific Testing Algorithm for Suspected Myeloproliferative Neoplasm
If essential thrombocythemia or other myeloproliferative neoplasm is suspected:
- Molecular testing sequence: JAK2 → CALR → MPL 3, 5
- Bone marrow biopsy showing: increased mature megakaryocytes in loose clusters for essential thrombocythemia 5
- Additional mutations to assess: TET2, ASXL1, DNMT3A, SF3B1 (prognostic value) 5
- Karyotype analysis: look for +9, 20q-, 13q- abnormalities 5
When to Involve Hematology Urgently
- Any blast cells on peripheral smear 1
- WBC >50 × 10⁹/L with thrombocytosis 4
- Unexplained pancytopenia or bicytopenia with one elevated cell line
- Abnormal cell morphology suggesting dysplasia 6
The key distinction: Reactive processes typically show polymorphic lymphocytosis or left-shifted granulocytes with toxic changes, while primary hematologic disorders demonstrate monomorphic populations, dysplastic features, or immature cells 2. Your clinical history should focus on recent infections, inflammatory conditions, medications (especially growth factors), transfusion history, and family history of hematologic disorders 1.